TRILURON
PMA P180040
Active
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMAAPPR | NumberP180040 | Date26 Mar 2019 | StatusActive |
Official records
- FDA PMA database P180040
From the FDA record
FDA PMA P180040
- Received by the FDA
- 27 Sep 2018
- FDA decision
- 26 Mar 2019
- FDA review time
- 180 days from receipt to decision
- Docket number
- 19M-1465
Approval for TRILURON. The device is indicated for use in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA PMA Active
Specification
- Full name
- TRILURON® (sodium hyaluronate)
- Trade name
- Triluron
- Generic name
- Acid, hyaluronic, intraarticular
- PMA number
- FDA product code
- MOZ
- Device class
- Class III
- Advisory committee
- Orthopedic
- FDA decision
- APPR Approved
Overview
AI-generated summary, 18 Sep 2026
TRILURON is an intraarticular hyaluronic acid injection indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics such as acetaminophen. It is a sterile, single-use product supplied in pre-filled syringes for injection into the knee joint.
TRILURON is manufactured by Fidia Farmaceutici S.p.A. and is supplied as a sterile, single-use device. It is intended for use in clinical settings by qualified healthcare professionals. The device has received FDA PMA approval (P180040) and is classified as a Class III medical device under the generic name Acid, hyaluronic, intraarticular.
Devices cleared under P180040
Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.
| UDI-DI | Size and differences | |||
|---|---|---|---|---|
| TRILURON 89122-0879-01 | 89122-0879-01 / 89122-0879-01 | M713891220879010 | — | On the market |
| TriLURON M71389122087901A13 | 89122-0879-01 / M71389122087901A13 | M71389122087901A1 | — | No longer on the market |
| TriLURON M71389122087901SAM1A | FID10000317 / M71389122087901SAM1A | M71389122087901SAM1 | — | No longer on the market |
Similar devices
Other devices filed under FDA product code MOZ (Acid, Hyaluronic, Intraarticular).
- Euflexxa (1% Sodium Hyaluronate) by Ferring Pharmaceuticals, Inc.
- Durolane by BIOVENTUS LLC
- Gel-Syn Acid, Hyaluronic, Intraarticular by Ibsa Institut Biochimique SA
- Monovisc Injectable Intra-Articular Device by Anika Therapeutics, Inc.
- SYNOJOYNT by Mesoblast
- TriVisc by Channel-Markers Medical, LLC
- Synvisc Hylan G-F 20 by Sanofi Genzyme Corp.
- Supartz by Seikagaku Corp.
- Gel-One by Seikagaku Corp.
- GenVisc 850 by Channel-Markers Medical, LLC